Sarcopenia Treatment Market by Treatment Type (Protein, Vitamin B12, Vitamin D & Calcium), Route of Administration (Oral, Injectable), End-User (Hospitals, Drug Stores & Retail Pharmacies, Online), & Region for 2026-2032

Sarcopenia Treatment Market Valuation - 2026-2032

The world's aging population is the main factor driving the sarcopenia treatment market since it raises the prevalence of the ailment, which lowers muscle mass and strength and has a serious negative impact on the quality of life for the elderly. As more people age, the demand for effective therapies and interventions grows, driven by increased knowledge of sarcopenia's negative health impacts and the importance of early detection and management. According to the analyst from Verified Market Research, the sarcopenia treatment market is estimated to reach a valuation of USD 444.23 Million over the forecast subjugating around USD 289.46 Million valued in 2024.

Furthermore, continuing research and development efforts are yielding new therapeutic alternatives, accelerating market expansion as healthcare practitioners and patients seek effective treatments for this age-related illness. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Sarcopenia Treatment Market: Definition/Overview

Sarcopenia treatment includes a variety of products and services aimed at preventing, managing, or alleviating sarcopenia, a degenerative disorder characterized by the loss of skeletal muscle mass, strength, and function, especially in older persons. Treatment strategies include nutritional interventions, such as protein, vitamin, and mineral supplements, as well as resistance training and physical therapies to improve muscular strength and functionality. Sarcopenia treatment can improve the quality of life for the aged by lowering the risk of falls and fractures, increasing mobility, managing associated metabolic disorders, supporting healthier aging, and preserving independence in everyday activities.

What are the Drivers Influencing the Growth of the Sarcopenia Treatment Market?

The growing older population worldwide is a major driver of the sarcopenia treatment market. According to the World Health Organization (WHO), the proportion of the global population over the age of 60 will nearly double between 2015 and 2050, from 12% to 22%. By 2050, 80% of the elderly will live in low- and middle-income countries. This demographic shift is critical since sarcopenia primarily affects elderly people. According to the International Osteoporosis Foundation, sarcopenia affects about 10% of those over the age of 60, with the frequency increasing to 50% in those over the age of 80.

Chronic conditions lead to or aggravate sarcopenia, increasing the need for treatment. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. Diabetes, which affects around 463 million adults globally, can speed up muscle loss. Sarcopenia is 15% more common in persons with type 2 diabetes than in those without the disease, according to studies.

Furthermore, the growing awareness among healthcare professionals and the development of better diagnostic tools are propelling the sarcopenia treatment market. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) modified its definition and diagnostic criteria for sarcopenia, resulting in more accurate identification of the condition. According to a study published in the Journal of Cachexia, Sarcopenia and Muscle, the prevalence of sarcopenia increased from 12.9% to 17.7% when the updated EWGSOP2 criteria were used instead of the original criteria. This enhanced diagnosis is projected to increase the demand for sarcopenia treatments.

What are the Key Challenges Associated with Adopting Sarcopenia Treatment?

The high expense of sarcopenia treatment and therapies presents a significant challenge for the market. Many effective therapies, such as nutritional supplements and specialist pharmaceuticals, are prohibitively expensive, making them inaccessible to a large percentage of the senior population. This financial barrier discouraged patients from seeking treatment or sticking to prescribed regimens, reducing the overall effectiveness of sarcopenia care and restricting market expansion.

Furthermore, social beliefs and stigmas associated with aging serve as a barrier to treatment. Many people are hesitant to seek treatment for sarcopenia because of misconceptions about aging and the belief that muscle loss is an unavoidable part of growing older. This hesitation leads to underdiagnosis and undertreatment, as those affected fail to grasp the need to tackle sarcopenia, limiting the market's growth potential.

Category-wise Acumens

How Does the Dominance of the Vitamin D & Calcium Supplements Segment Propel the Market?

According to VMR analyst, the vitamin D & calcium supplement segment is anticipated to dominate the segment within the sarcopenia treatment market during the forecast period. The importance of Vitamin D in muscular health adds greatly to the segment's prominence. Vitamin D is required for calcium absorption and bone metabolism, which are critical for muscular function. According to research, adequate levels of Vitamin D can help minimize the incidence of sarcopenia, especially in older persons, resulting in growing demand for these supplements as muscle loss prevention strategies.

The increasing knowledge of sarcopenia's negative effects on health is another driver of the market. As more people become aware of the problems connected with muscle loss, there is a greater emphasis on nutritional solutions to counteract the condition. Vitamin D and calcium supplements are highlighted in educational efforts directed at older persons, driving their usage as part of a proactive strategy to preserve muscle strength and overall health.

Furthermore, the rising prevalence of Vitamin D deficiency among the elderly is a major factor driving demand for Vitamin D and calcium supplements. Many older persons have low Vitamin D levels because of restricted sun exposure and nutritional intake, so supplementation is an important technique for preventing sarcopenia. The increased knowledge of deficiency-related hazards has resulted in a spike in demand for these specific supplements as effective treatment options.

How does the Increasing Hospitalization Rates Contribute to the Demand for Hospitals?

The hospital segment is estimated to hold the largest share of the sarcopenia treatment market during the forecast period. The rising hospitalization rates of elderly people experiencing problems from sarcopenia are a major contributing factor. As the population ages, more people may need medical attention for falls, fractures, and other muscle-related health concerns. Hospitals have an important role in delivering complete care, including diagnosis, treatment, and rehabilitation, which increases the demand for sarcopenia treatments in these settings.

Hospitals' domination is further aided by the availability of specialized healthcare professionals and resources. Hospitals have interdisciplinary teams of geriatricians, dietitians, and physical therapists who can work together to meet the complicated needs of sarcopenic patients. This comprehensive strategy improves treatment efficacy and patient outcomes, making hospitals the optimal setting for managing sarcopenia.

Furthermore, insurance coverage and reimbursement policies frequently favor hospital-based therapies, making them more accessible for patients. Many health insurance policies offer better coverage for hospital-administered treatments than those bought from pharmacy stores or online pharmacies. This financial incentive encourages patients to seek therapy in hospitals, reinforcing the hospital segment's dominant position in the sarcopenia treatment market.

Country/Region-wise Acumens

How Does the High Prevalence of Chronic Diseases Associated with Sarcopenia in Asia Pacific Propel the Market?

According to VMR analysis, the Asia Pacific region is estimated to dominate in sarcopenia treatment market during the forecast period. The Asia Pacific area has a high prevalence of chronic diseases related to sarcopenia, which drives the market. According to the International Diabetes Federation, the Western Pacific region (which comprises the majority of East Asia and Oceania) had the highest number of diabetic adults (163 million) in 2019. This number is predicted to increase to 212 million by 2045. Diabetes is known to accelerate muscle loss, with research indicating that the prevalence of sarcopenia in Asian people with type 2 diabetes is approximately 14.8%, which is much greater than in non-diabetic persons.

Furthermore, the growing healthcare spending and improved diagnostic capabilities in the Asia Pacific region are propelling the sarcopenia treatment market. According to the World Bank, health spending per capita in East Asia and the Pacific rose from $571 in 2010 to $937 in 2019, showing a growing investment in healthcare. In China, one of the region's largest marketplaces, health spending per capita has more than doubled, from $289 in 2010 to $731 in 2019. This increased funding allows for better detection and treatment of illnesses such as sarcopenia.

What are the Drivers Bolstering the Sarcopenia Treatment Market in North America?

North America is estimated to exhibit substantial growth within the market during the forecast period. North America has a huge and expanding older population, which drives the sarcopenia treatment market. According to the United States Census Bureau, the number of Americans aged 65 and up is expected to nearly double, from 52 million in 2018 to 95 million by 2060. Sarcopenia is highly prevalent in North America. According to a study published in the Journal of Cachexia, Sarcopenia, and Muscle, the prevalence of sarcopenia in the United States varies between 10% and 40% among persons aged 60 and older, depending on the diagnostic criteria utilized. This high frequency indicates a sizable market for sarcopenia treatments.

Furthermore, North America, particularly the United States, has high rates of obesity and accompanying metabolic problems, which are directly tied to sarcopenia. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017-2018. According to data from the National Health and Nutrition Examination Survey (NHANES), the prevalence of sarcopenic obesity among older persons in the United States ranges from 4% to 25%, depending on the definition. The increased incidence of obesity, particularly sarcopenic obesity, is driving the need for comprehensive sarcopenia treatments that target both muscle loss and metabolic health.

Competitive Landscape

The sarcopenia treatment market is competitive, with several significant competitors contending for market share. Large companies are focusing on strategic initiatives such as new product launches, mergers and acquisitions, and research and development efforts to increase their market position.

Some of the prominent players operating in the sarcopenia treatment market include:

Nestle Health Science

Sanofi S.A.

Bayer AG

Haleon Group of Companies

Novartis AG

Abbott Laboratories

Metagenics LLC

Pfizer, Inc.

GlaxoSmithKline plc.

Makers Nutrition LLC

Latest Developments:

In July 2024, Abbott Laboratories launched clinical research to assess the efficacy of its novel protein supplement designed exclusively for sarcopenia sufferers. The study's goal is to examine improvements in muscle strength and functionality among older persons, reinforcing Abbott's emphasis on new solutions to age-related health issues.

In June 2024, Pfizer Inc. announced a collaboration with various academic institutions to enhance sarcopenia research. This collaboration intends to investigate the potential of new pharmacological therapy paired with nutritional interventions, demonstrating Pfizer's commitment to addressing the growing concerns about muscle loss in the elderly population.

Sarcopenia Treatment Market, by Category

Treatment Type:

Protein Supplements

Vitamin B12 Supplements

Vitamin D & Calcium Supplements

Others

Route of Administration:

Oral

Injectable

Others

End-User:

Hospitals

Drug Stores and Retail Pharmacies

Online Pharmacies

Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa